HUP0400757A2 - Protein kináz gátló hatású kondenzált pirazolszármazékok és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Protein kináz gátló hatású kondenzált pirazolszármazékok és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0400757A2
HUP0400757A2 HU0400757A HUP0400757A HUP0400757A2 HU P0400757 A2 HUP0400757 A2 HU P0400757A2 HU 0400757 A HU0400757 A HU 0400757A HU P0400757 A HUP0400757 A HU P0400757A HU P0400757 A2 HUP0400757 A2 HU P0400757A2
Authority
HU
Hungary
Prior art keywords
alkyl
nr7r8
alkenyl
hydrogen
pharmaceutical compositions
Prior art date
Application number
HU0400757A
Other languages
English (en)
Hungarian (hu)
Inventor
Michael John Alberti
Ian Robert Baldwin
Mui Cheung
Stuart Cockerill
Stephen Flack
Philip Anthony Harris
David Kendall Jung
Gregory Peckham
Michael Robert Peel
Jennifer Badiang Stanford
Kirk Stevens
James Marvin Veal
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0020556.7A external-priority patent/GB0020556D0/en
Priority claimed from GB0020576A external-priority patent/GB0020576D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of HUP0400757A2 publication Critical patent/HUP0400757A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
HU0400757A 2000-08-22 2001-08-22 Protein kináz gátló hatású kondenzált pirazolszármazékok és ezeket tartalmazó gyógyszerkészítmények HUP0400757A2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0020556.7A GB0020556D0 (en) 2000-08-22 2000-08-22 Fused pyrazole derivatives
GB0020576A GB0020576D0 (en) 2000-08-22 2000-08-22 Fused pyrazole derivatives
PCT/GB2001/003783 WO2002016359A1 (en) 2000-08-22 2001-08-22 Fused pyrazole derivatives being protein kinase inhibitors

Publications (1)

Publication Number Publication Date
HUP0400757A2 true HUP0400757A2 (hu) 2004-07-28

Family

ID=26244869

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400757A HUP0400757A2 (hu) 2000-08-22 2001-08-22 Protein kináz gátló hatású kondenzált pirazolszármazékok és ezeket tartalmazó gyógyszerkészítmények

Country Status (19)

Country Link
US (1) US7166597B2 (enExample)
EP (1) EP1311507B1 (enExample)
JP (1) JP2004506736A (enExample)
KR (1) KR20030040419A (enExample)
AR (1) AR034261A1 (enExample)
AT (1) ATE318814T1 (enExample)
AU (1) AU2001282318A1 (enExample)
BR (1) BR0113448A (enExample)
CA (1) CA2420024A1 (enExample)
DE (1) DE60117568T2 (enExample)
ES (1) ES2259331T3 (enExample)
HU (1) HUP0400757A2 (enExample)
IL (1) IL154402A0 (enExample)
MX (1) MXPA03001593A (enExample)
NO (1) NO20030779L (enExample)
PE (1) PE20020506A1 (enExample)
PL (1) PL362130A1 (enExample)
UY (1) UY26899A1 (enExample)
WO (1) WO2002016359A1 (enExample)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
EP1377573B1 (en) 2000-12-15 2005-07-27 Glaxo Group Limited Pyrazolopyridine derivatives
JP2004518651A (ja) * 2000-12-15 2004-06-24 グラクソ　グループ　リミテッド 治療用化合物
US7153855B2 (en) * 2001-03-08 2006-12-26 Smithkline Beecham Corporation Pyrazolopyridinyl pyrimidine therapeutic compounds
US7034030B2 (en) 2001-03-30 2006-04-25 Smithkline Beecham Corporation Pyralopyridines, process for their preparation and use as therapeutic compounds
GB0108770D0 (en) * 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
JP4219171B2 (ja) * 2001-04-10 2009-02-04 スミスクライン ビーチャム コーポレーション 抗ウイルス性ピラゾロピリジン化合物
US6962914B2 (en) 2001-04-27 2005-11-08 Smithkline Beecham Corporation Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds
US7087626B2 (en) 2001-05-24 2006-08-08 Eli Lilly And Company Pyrrole derivatives as pharmaceutical agents
CA2451008A1 (en) 2001-06-21 2003-01-03 Smithkline Beecham Corporation Imidazo[1,2-a!pyridine derivatives for the prophylaxis and treatment of herpes viral infections
US20040235794A1 (en) * 2001-09-04 2004-11-25 Shinji Nakade Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
ES2262893T3 (es) 2001-10-05 2006-12-01 Smithkline Beecham Corporation Derivados de imidazo-piridina para su uso en el tratamiento de infeccion virica por herpes.
GB0124932D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
AU2002357740A1 (en) 2001-12-11 2003-06-23 Smithkline Beecham Corporation Pyrazolo-pyridine derivatives as antiherpes agents
WO2003068747A1 (en) 2002-02-12 2003-08-21 Smithkline Beecham Corporation Nicotinamide derivates useful as p38 inhibitors
WO2003082869A1 (en) 2002-03-28 2003-10-09 Eisai Co., Ltd. Azaindoles as inhibitors of c-jun n-terminal kinases
AU2003214412A1 (en) 2002-03-28 2003-10-13 Eisai R & D Management Co., Ltd. 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
GB0209891D0 (en) * 2002-04-30 2002-06-05 Glaxo Group Ltd Novel compounds
WO2003095455A2 (en) 2002-05-10 2003-11-20 Smithkline Beecham Corporation Substituted pyrazolopyrimidines
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
GB0217783D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
EP1539748A1 (en) * 2002-07-31 2005-06-15 Smithkline Beecham Corporation 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
GB0217757D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
CN1681502A (zh) 2002-09-18 2005-10-12 辉瑞产品公司 作为转化生长因子(tgf)抑制剂的三唑类衍生物
JP2006506443A (ja) 2002-09-18 2006-02-23 ファイザー・プロダクツ・インク 形質転換成長因子（ｔｇｆ）阻害剤としての新規なイソチアゾール及びイソキサゾール化合物
HRP20050250A2 (en) 2002-09-18 2005-10-31 Pfizer Products Inc. Novel triazole and oxazole compounds as transforming growth factor (tfg) inhibitor
CA2498047C (en) 2002-09-18 2009-05-19 Pfizer Products Inc. Novel imidazole compounds as transforming growth factor (tgf) inhibitors
CA2496295C (en) 2002-09-18 2010-11-23 Michael John Munchhof Novels pyrazole compounds as transforming growth factor (tgf) inhibitors
AU2003275266A1 (en) * 2002-10-03 2004-05-04 Smithkline Beecham Corporation Therapeutic compounds based on pyrazolopyridine derivatives
ATE481402T1 (de) 2003-02-27 2010-10-15 Palau Pharma Sa Pyrazolopyridin-derivate
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
GB0305142D0 (en) 2003-03-06 2003-04-09 Eisai London Res Lab Ltd Synthesis
WO2004101565A2 (en) 2003-05-16 2004-11-25 Eisai Co., Ltd. Jnk inhibitors
SE0301906D0 (sv) * 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
GB0318814D0 (en) * 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
GB0402143D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402140D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402138D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
MY143245A (en) * 2004-04-28 2011-04-15 Mitsubishi Tanabe Pharma Corp 4- 2-(cycloalkylamino)pyrimidin-4-yl-(phenyl)-imidazolin-2-one derivatives as p38 map-kinase inhibitors for the treatment of inflammatory diseases
AU2005251735A1 (en) * 2004-06-04 2005-12-22 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
US20080051416A1 (en) * 2004-10-05 2008-02-28 Smithkline Beecham Corporation Novel Compounds
WO2006038001A1 (en) * 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
US7485725B1 (en) * 2004-11-12 2009-02-03 Frontier Scientific, Inc. Substituted pyridines
US7812022B2 (en) 2004-12-21 2010-10-12 Glaxosmithkline Llc 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors
DE602005014382D1 (de) * 2004-12-21 2009-06-18 Smithkline Beecham Corp 2-pyrimidinyl-pyrazolopyridin-erbb-kinaseinhibitoren
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
EP1971606B1 (en) * 2005-12-05 2013-04-24 GlaxoSmithKline LLC 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
CN101374941A (zh) 2005-12-29 2009-02-25 人类起源公司 采集和保存胎盘干细胞的改良组合物及其使用方法
CA2654498A1 (en) * 2006-06-06 2007-12-21 Avigen, Inc. Substituted pyrazolo[1,5-.alpha.]pyridine compounds and their methods of use
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US8158656B2 (en) * 2008-05-16 2012-04-17 Shenzhen Chipscreen Biosciences Ltd. 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
UA106724C2 (uk) * 2008-06-30 2014-10-10 Янссен Фармацевтика Нв Спосіб отримання заміщених піримідинових похідних
US8048887B2 (en) 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7994171B2 (en) 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8198449B2 (en) * 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8293909B2 (en) 2008-09-11 2012-10-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
JP2012527461A (ja) * 2009-05-19 2012-11-08 ダウ アグロサイエンシィズ エルエルシー 真菌を防除するための化合物および方法
US8211901B2 (en) 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
CN101906076B (zh) 2009-06-04 2013-03-13 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
US20110039873A1 (en) * 2009-06-08 2011-02-17 Gaeta Federico C A SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY
US8502789B2 (en) 2010-01-11 2013-08-06 Smart Technologies Ulc Method for handling user input in an interactive input system, and interactive input system executing the method
UY33213A (es) * 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
EP2360158A1 (en) * 2010-02-18 2011-08-24 Almirall, S.A. Pyrazole derivatives as jak inhibitors
US8324212B2 (en) 2010-02-25 2012-12-04 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8354410B2 (en) 2010-03-11 2013-01-15 Bristol-Meyers Squibb Company Compounds for the treatment of hepatitis C
EP2402335A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
EP2402336A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
US8445497B2 (en) 2010-06-30 2013-05-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
WO2013050434A1 (en) * 2011-10-06 2013-04-11 Bayer Intellectual Property Gmbh Heterocyclylpyri(mi)dinylpyrazole
US9303020B2 (en) 2012-02-08 2016-04-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
HUE037600T2 (hu) 2012-11-19 2018-09-28 Novartis Ag Vegyületek és készítmények paraziták által okozott fertõzések kezelésére
GB201321733D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
JP2017500362A (ja) * 2013-12-26 2017-01-05 イグナイタ インコーポレイテッド ピラゾロ［１，５−ａ］ピリジン誘導体およびその使用方法
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
CN109476696B (zh) * 2016-06-02 2022-06-10 细胞基因公司 动物及人抗锥虫和抗利什曼原虫剂
EP3464287B1 (en) * 2016-06-02 2022-06-08 Celgene Corporation Animal and human anti-malarial agents
CN111601593B (zh) 2017-10-05 2022-04-15 弗尔康医疗公司 P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN110563626B (zh) * 2019-09-04 2023-03-10 天津中医药大学 一种1h-氮杂环丙烯类化合物及其合成方法
MX2023001236A (es) * 2020-08-05 2023-03-03 Massachusetts Gen Hospital Inhibidores de cinasa inducibles por sal.
WO2024026410A2 (en) * 2022-07-29 2024-02-01 Baylor College Of Medicine Neurotrophic receptor tyrosine kinase (ntrk) inhibitors and methods using same

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) * 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
EP0151962A3 (en) * 1984-01-25 1985-10-02 Beecham Group Plc Pyrazolopyridine derivatives
GB8404584D0 (en) * 1984-02-22 1984-03-28 Beecham Group Plc Compounds
GB8404586D0 (en) * 1984-02-22 1984-03-28 Beecham Group Plc Compounds
US5002941A (en) 1985-12-12 1991-03-26 Smithkline Beecham Corporation Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
US5155114A (en) * 1989-01-23 1992-10-13 Fujisawa Pharmaceutical Company, Ltd. Method of treatment using pyrazolopyridine compound
EP0346841A3 (de) 1988-06-16 1991-01-09 Ciba-Geigy Ag 1-Aryl-naphthoesäureamide und diese enthaltende mikrobizide Mittel
GB8901423D0 (en) 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
JPH05503919A (ja) 1989-06-13 1993-06-24 スミスクライン・ビーチャム・コーポレイション 単球および／またはマクロファージによるインターロイキン―１または腫瘍壊死因子生成の抑制
AU622330B2 (en) * 1989-06-23 1992-04-02 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
EP0430033A3 (en) 1989-11-24 1991-09-11 Ciba-Geigy Ag Microbicidal agents
JPH05508153A (ja) 1990-06-12 1993-11-18 スミスクライン・ビーチャム・コーポレイション ５―リポキシゲナーゼ経路およびシクロオキシゲナーゼ経路で媒介される疾患の阻害
GB9015764D0 (en) 1990-07-18 1990-09-05 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
ATE211384T1 (de) 1991-01-29 2002-01-15 Fujisawa Pharmaceutical Co Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
GB9107513D0 (en) * 1991-04-10 1991-05-29 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
DK0533268T3 (da) 1991-09-18 2001-12-03 Glaxo Group Ltd Benzanilidderivater som 5HT-1D antagonister
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5236934A (en) * 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
TW240217B (enExample) 1992-12-30 1995-02-11 Glaxo Group Ltd
GB2273930A (en) 1992-12-30 1994-07-06 Glaxo Group Ltd Benzanilide derivatives
US5300478A (en) * 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
IL108630A0 (en) * 1993-02-18 1994-05-30 Fmc Corp Insecticidal substituted 2,4-diaminoquinazolines
GB2276161A (en) 1993-03-17 1994-09-21 Glaxo Group Ltd Aniline and benzanilide derivatives
GB2276162A (en) 1993-03-17 1994-09-21 Glaxo Group Ltd Aniline and benazilide derivatives
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
DK0716649T3 (da) 1993-08-31 1999-02-08 Pfizer 5-Arylindolderivater
EP0716656A1 (en) 1993-09-03 1996-06-19 Smithkline Beecham Plc Amide derivatives as 5ht1d receptor antagonists
EP0724580A1 (en) 1993-10-19 1996-08-07 Smithkline Beecham Plc Benzanilide derivatives as 5ht-1d receptor antagonists
US5801170A (en) 1993-12-07 1998-09-01 Smithkline Beecham Plc Heterocyclic biphenylylamides useful as 5HT1D antagonists
GB9326008D0 (en) 1993-12-21 1994-02-23 Smithkline Beecham Plc Novel compounds
GB9408577D0 (en) 1994-04-29 1994-06-22 Fujisawa Pharmaceutical Co New compound
EP0758330A1 (en) 1994-05-06 1997-02-19 Smithkline Beecham Plc Biphenylcarboxamides useful as 5-ht1d antagonists
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US5552422A (en) * 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
CZ313397A3 (cs) * 1995-04-04 1998-03-18 Glaxo Group Limited Imidazo/1,2a/pyridinové deriváty, způsob jejich výroby a farmaceutický prostředek s jejich obsahem
GB9507203D0 (en) 1995-04-07 1995-05-31 Smithkline Beecham Plc Novel compounds
IL118544A (en) * 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
AU6111796A (en) 1995-06-12 1997-01-09 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5 -lipoxygenase inhibitor
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
US6342510B1 (en) 1995-06-12 2002-01-29 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist
CA2226849A1 (en) 1995-07-10 1997-01-30 Zenon Lysenko Stable polynitrile oxides and their use as curing agent especially for latex
EP1304322A3 (en) * 1995-08-22 2003-11-19 Japan Tobacco Inc. Carboxylic acid compound and use thereof
JP2000503302A (ja) * 1996-01-11 2000-03-21 スミスクライン・ビーチャム・コーポレイション 新規置換イミダゾール化合物
FR2757059B1 (fr) 1996-12-12 1999-01-29 Rhone Poulenc Rorer Sa Nouvelle application therapeutique des derives du pyrrole
FR2757166B1 (fr) * 1996-12-12 1999-01-29 Rhone Poulenc Rorer Sa Derives du pyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5945418A (en) * 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
AU7132998A (en) * 1997-04-24 1998-11-13 Ortho-Mcneil Corporation, Inc. Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
CN1264376A (zh) * 1997-05-22 2000-08-23 G·D·瑟尔公司 作为p38激酶抑制剂的3(5)－杂芳基取代的吡唑化合物
US6087496A (en) * 1998-05-22 2000-07-11 G. D. Searle & Co. Substituted pyrazoles suitable as p38 kinase inhibitors
JP2002504909A (ja) * 1997-06-13 2002-02-12 スミスクライン・ビーチャム・コーポレイション 新規な置換ピラゾールおよびピラゾリン化合物
EP1019396A1 (en) * 1997-07-02 2000-07-19 SmithKline Beecham Corporation Novel cycloalkyl substituted imidazoles
ES2203985T3 (es) * 1997-09-05 2004-04-16 Glaxo Group Limited Derivados de 2,3-diaril-pirazolo(1,5)piridazina, su preparacion y su uso como inhibidores de la ciclooxigenasa 2(cox-2)`.
IL136737A0 (en) 1997-12-22 2001-06-14 Bayer Ag Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
DE19817461A1 (de) * 1998-04-20 1999-10-21 Basf Ag Neue substituierte Benzamide, deren Herstellung und Anwendung
EP1077971A1 (en) 1998-05-14 2001-02-28 G.D. SEARLE & CO. 1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
PT1077931E (pt) * 1998-05-15 2005-03-31 Astrazeneca Ab Derivados de bezamida para o tratamento de doencas mediadas por citocinas
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
US6130235A (en) * 1998-05-22 2000-10-10 Scios Inc. Compounds and methods to treat cardiac failure and other disorders
FR2779724B1 (fr) 1998-06-10 2001-04-20 Rhone Poulenc Rorer Sa Derives du pyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent
CA2342251A1 (en) 1998-08-28 2000-03-09 Scios Inc. Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
EP1114039A1 (en) * 1998-09-18 2001-07-11 Vertex Pharmaceuticals Incorporated INHIBITORS OF p38
ATE275148T1 (de) 1998-11-03 2004-09-15 Glaxo Group Ltd Pyrazolopyridin derivative als selektive cox-2 inhibitoren
EP1142890B1 (en) * 1998-12-25 2005-08-03 Teikoku Hormone Mfg. Co., Ltd. Aminopyrazole derivatives
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1157025B1 (en) 1999-02-27 2004-03-10 Glaxo Group Limited Pyrazolopyridines
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
US6509361B1 (en) * 1999-05-12 2003-01-21 Pharmacia Corporation 1,5-Diaryl substituted pyrazoles as p38 kinase inhibitors
WO2000071509A1 (en) 1999-05-24 2000-11-30 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
EP1196379A2 (en) 1999-05-24 2002-04-17 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
CA2374650A1 (en) * 1999-05-24 2000-11-30 Penglie Zhang Inhibitors of factor xa
CZ20014573A3 (cs) 1999-06-28 2002-05-15 Janssen Pharmaceutica N. V. Inhibitory replikace respiračně syncyciálního viru
GB9919778D0 (en) * 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
BR0007447A (pt) 1999-11-10 2002-04-09 Ortho Mcneil Pharm Inc 2-aril-3-(heteroaril)-imidazo[1,2-a]pirimidinas substituìdas, composições farmacêuticas e métodos
TWI282334B (en) 2000-03-22 2007-06-11 22 2001 00 00 0 A61p 17/00 200601 a i vhtw a61p 29/00 200601 a i vhtw a61p 35/00 200601 a i vhtw a61p 37/00 200601 a i vhtw
EP1276742B1 (en) 2000-04-28 2004-06-09 Glaxo Group Limited Process for the preparation of pyrazolopyridine derivatives
CN1429223A (zh) 2000-05-18 2003-07-09 第一制药株式会社 新颖苯并呋喃衍生物
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AUPQ969800A0 (en) 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
DK1363910T3 (da) 2000-11-17 2006-06-26 Bristol Myers Squibb Co Fremgangsmåder til behandling af P39-kinase-associerede tilstande og pyrrolotriazinforbindelser, der er anvendelige som kinase-inhibitorer
JP2004518651A (ja) 2000-12-15 2004-06-24 グラクソ　グループ　リミテッド 治療用化合物
EP1377573B1 (en) 2000-12-15 2005-07-27 Glaxo Group Limited Pyrazolopyridine derivatives
DE10063008A1 (de) 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
DE10110749A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
US6962914B2 (en) * 2001-04-27 2005-11-08 Smithkline Beecham Corporation Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds
US6756498B2 (en) * 2001-04-27 2004-06-29 Smithkline Beecham Corporation Process for the preparation of chemical compounds
US7196095B2 (en) 2001-06-25 2007-03-27 Merck & Co., Inc. (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
GB0124932D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124928D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
WO2003068747A1 (en) 2002-02-12 2003-08-21 Smithkline Beecham Corporation Nicotinamide derivates useful as p38 inhibitors
GB0209891D0 (en) 2002-04-30 2002-06-05 Glaxo Group Ltd Novel compounds
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
US20040038014A1 (en) * 2002-08-20 2004-02-26 Donaldson Company, Inc. Fiber containing filter media
GB0308201D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
DE602004017494D1 (de) * 2003-07-25 2008-12-11 Novartis Ag Inhibitoren von p-38-kinase
GB0318814D0 (en) 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
GB0329572D0 (en) 2003-12-20 2004-01-28 Astrazeneca Ab Amide derivatives

Also Published As

Publication number Publication date
EP1311507B1 (en) 2006-03-01
UY26899A1 (es) 2002-03-22
DE60117568D1 (de) 2006-04-27
PE20020506A1 (es) 2002-07-09
NO20030779L (no) 2003-04-07
AR034261A1 (es) 2004-02-18
DE60117568T2 (de) 2006-08-24
MXPA03001593A (es) 2003-06-04
IL154402A0 (en) 2003-09-17
KR20030040419A (ko) 2003-05-22
CA2420024A1 (en) 2002-02-28
US7166597B2 (en) 2007-01-23
BR0113448A (pt) 2003-06-17
AU2001282318A1 (en) 2002-03-04
NO20030779D0 (no) 2003-02-19
EP1311507A1 (en) 2003-05-21
ES2259331T3 (es) 2006-10-01
JP2004506736A (ja) 2004-03-04
WO2002016359A1 (en) 2002-02-28
ATE318814T1 (de) 2006-03-15
PL362130A1 (en) 2004-10-18
US20040053942A1 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
HUP0400757A2 (hu) Protein kináz gátló hatású kondenzált pirazolszármazékok és ezeket tartalmazó gyógyszerkészítmények
HUP0402352A2 (hu) Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
TR200200778T2 (tr) Pirazol türevleri.
HUP0004529A2 (hu) VLA-4 által mediált leukocita adhéziót gátló szulfonilezett dipeptid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint alkalmazásuk
HUP0402313A2 (hu) Szerotonin újrafelvételt gátló fenilpiperazin-származékok, az ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
AR024969A1 (es) Derivados de 8-fenil-6,9-dihidro-[1,2,4]triazol[3,4-i]purin-5-ona
NZ331319A (en) Cyclic amine derivatives that are CCR-3 receptor (chemokine receptor) antagonists, compositions containing them and methods for their use (to combat eosinophil induced diseases).
DK1412354T3 (da) Derivater af triazolylimidazopyridin og af triazolylpurinerne, der er egnede som ligander for adenosin A2a?-receptoren og deres anvendelse som medikamenter
HUP0401335A2 (hu) Herbicid hatású [(piridil-propinil)-oxi]-fenil-származékok, előállításuk és alkalmazásuk
HUP0302969A2 (hu) NPY Y5 antagonisták, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0001243A2 (hu) Nikotinamidszármazékok és a vegyületeket tartalmazó gyógyszerészeti készítmények
DE69501947D1 (de) SUBSTITUIERTE AROMATISCHE VERBINDUNGEN ALS c. AMP PHOSPHODIESTERASE-UND TNF-HEMMER
DK0958296T3 (da) Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme
DE60017115D1 (de) Amid-derivate und deren medizinische verwendung
TR200003256T2 (tr) P-38 mapkinaz engelleyicileri olan pirazol türevleri
DK0389282T3 (da) Xanthinderivater, fremgangsmåde til deres fremstilling og deres farmaceutiske anvendelse
CY1116183T1 (el) Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης
BR9915475A (pt) Derivados da quinolina-4-carboxamida comoantagonistas dos receptores de nk-3 e nk-2
HUP0400246A2 (hu) 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra
ATE194345T1 (de) Xanthinderivate
TR200402529T4 (tr) Yeni Fenalliloksi fenil türevleri.
MY116952A (en) 4 substituted 2-carboxy-tetrahydroquinoline derivatives, pharmaceutical compositions comprising them and process for their preparation
HUP0402261A2 (hu) Piperidinszármazékok és alkalmazásuk kemokin receptor aktivitás modulátoraiként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DE60001586D1 (de) Diphenyl-piperidin derivate
ATE307812T1 (de) Imidazopyridinverbindungen als 5-ht4- rezeptormodulatoren